A Prognostic Binary Classifier Comprised of Five Critical MRNAs Stratified Pancreatic Cancer Patients Following Resection

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jun 3

PMID 38828350

Authors

Yueqing Lu

Tong Zhou

Mingshu Lu

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is characterized by an extremely poor prognosis, even following potentially curative resection. Classical prognostic markers such as histopathological or clinical parameters have limited predictive power. The present study aimed to establish a prognostic model combining mRNA expression data with histopathological and clinical data to better predict survival and stratify pancreatic cancer patients following resection. We pioneered three models in one study and systematically evaluated the clinical benefits of all three models.

Methods: To identify differentially expressed genes in pancreatic cancer, mRNA data from normal (GTEx database) and pancreatic cancer (TCGA database) tissues were used. Survival analysis was carried out to identify prognosis-relevant genes from the identified differentially expressed genes and LASSO regression was used to filter out hub genes. The risk score of several hub genes was calculated according to gene expression and coefficients. Validation was carried out using an independent set of GEO microarray data. Multivariate COX regression was used for identifying independent clinical and pathological risk factors related to patient's survival in the TCGA database and a prognostic model combining mRNA expression data with histopathological and clinical data was established. Another prognostic model using clinicopathological factors from the SEER database was conceived based on multivariate COX regression. NRI (net reclassification improvement) and IDI (integrated discrimination index) were used to compare the predictive capabilities of the different models.

Results: We identified 1589 differentially expressed genes (DEGs) through the comparison of normal and pancreatic cancer tissues, of whom 317 were associated with prognosis(p < 0.05). LASSO regression identified five hub genes, MYEOV, ANXA2P2, MET, CEP55, and KRT7, that were used for the five-mRNA-classifier prognostic model. The classifier could stratify patients into a short and long survival group: 5-year overall survival in the training set (TCGA, 6 % vs 52 %, p < 0.001), test set (TCGA, 18 % vs 55 %,p < 0.01) and external validation set (GEO, 0 % vs 25 %, p < 0.05). Sensitivity analysis showed that the mRNA model (model 1) was better than the clinicopathological no-mRNA model (model 2) in predicting 5-year survival in the TCGA database (AUC: 0.877 vs 0.718, z = 3.165, p < 0.01) and better than the multi-factor prognostic model (model 3) from the SEER database (AUC: 0.754, z = 2.637, p < 0.01). On predictive performance, model 1 improved model 2 (NRI = 0.084, z = 1.288, p = 0.198; IDI = 0.055, z = 1.041,p = 0.298) and model 3 (NRI = 0.167,z = 1.961,p = 0.05; IDI = 0.086, z = 1.427, p = 0.154).

Conclusion: The five-mRNA-classifier is a reliable and feasible instrument to predict the prognosis of pancreatic cancer patients following resection. It might help in patiens counseling and assist clinicians in providing individualized treatment for patients in different risk groups.

References

Li E, Huang X, Zhang G, Liang T . Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res. 2021; 40(1):279. PMC: 8414725. DOI: 10.1186/s13046-021-02055-w. View

Liang E, Lu Y, Shi Y, Zhou Q, Zhi F . MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity. Oncogene. 2020; 39(41):6437-6450. DOI: 10.1038/s41388-020-01443-4. View

Van Calster B, Wynants L, Verbeek J, Verbakel J, Christodoulou E, Vickers A . Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol. 2018; 74(6):796-804. PMC: 6261531. DOI: 10.1016/j.eururo.2018.08.038. View

Wang W, Wang J, Yang C, Wang J . MicroRNA-216a targets WT1 expression and regulates KRT7 transcription to mediate the progression of pancreatic cancer-A transcriptome analysis. IUBMB Life. 2021; 73(6):866-882. DOI: 10.1002/iub.2468. View

Ko A . Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope?. JAMA Oncol. 2015; 2(3):380-1. DOI: 10.1001/jamaoncol.2015.4869. View

van Roessel S, Kasumova G, Verheij J, Najarian R, Maggino L, De Pastena M . International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. JAMA Surg. 2018; 153(12):e183617. PMC: 6583013. DOI: 10.1001/jamasurg.2018.3617. View

Ma X, Cui Z, Du Z, Lin H . Transforming growth factor-β signaling, a potential mechanism associated with diabetes mellitus and pancreatic cancer?. J Cell Physiol. 2020; 235(9):5882-5892. DOI: 10.1002/jcp.29605. View

Tange S, Hirano T, Idogawa M, Hirata E, Imoto I, Tokino T . MYEOV overexpression induced by demethylation of its promoter contributes to pancreatic cancer progression via activation of the folate cycle/c-Myc/mTORC1 pathway. BMC Cancer. 2023; 23(1):85. PMC: 9875418. DOI: 10.1186/s12885-022-10433-6. View

Tang R, Ji J, Ding J, Huang J, Gong B, Zhang X . Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma. Cell Cycle. 2020; 19(13):1602-1610. PMC: 7469688. DOI: 10.1080/15384101.2020.1757243. View

10.

Wu B, Wang Z, Lin N, Yan X, Lv Z, Ying Z . A panel of eight mRNA signatures improves prognosis prediction of osteosarcoma patients. Medicine (Baltimore). 2021; 100(14):e24118. PMC: 8036027. DOI: 10.1097/MD.0000000000024118. View

11.

Kamisawa T, Wood L, Itoi T, Takaori K . Pancreatic cancer. Lancet. 2016; 388(10039):73-85. DOI: 10.1016/S0140-6736(16)00141-0. View

12.

Chang X, Liu X, Wang H, Yang X, Gu Y . Glycolysis in the progression of pancreatic cancer. Am J Cancer Res. 2022; 12(2):861-872. PMC: 8900001. View

13.

Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J . Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int. 2019; 2019:2408348. PMC: 6885833. DOI: 10.1155/2019/2408348. View

14.

Jeong M, Urquhart G, Lewis C, Chi Z, Jewell J . Inhibition of phosphodiesterase 4D suppresses mTORC1 signaling and pancreatic cancer growth. JCI Insight. 2023; 8(13). PMC: 10371348. DOI: 10.1172/jci.insight.158098. View

15.

Connor A, Gallinger S . Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2021; 22(3):131-142. DOI: 10.1038/s41568-021-00418-1. View

16.

Song J, Ruze R, Chen Y, Xu R, Yin X, Wang C . Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer. BMC Cancer. 2022; 22(1):894. PMC: 9380297. DOI: 10.1186/s12885-022-09983-6. View

17.

Firuzi O, Che P, Hassouni B, Buijs M, Coppola S, Lohr M . Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers (Basel). 2019; 11(5). PMC: 6562408. DOI: 10.3390/cancers11050638. View

18.

Pencina M, DAgostino Sr R, DAgostino Jr R, Vasan R . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2007; 27(2):157-72. DOI: 10.1002/sim.2929. View

19.

Xu J, Xu W, Yang X, Liu Z, Zhao Y, Sun Q . LncRNA MIR99AHG mediated by FOXA1 modulates NOTCH2/Notch signaling pathway to accelerate pancreatic cancer through sponging miR-3129-5p and recruiting ELAVL1. Cancer Cell Int. 2021; 21(1):674. PMC: 8675481. DOI: 10.1186/s12935-021-02189-z. View

20.

Wang Q, Shi L, Sun F, Zhang Y, Chen R, Yang S . High Expression of Pseudogene Promotes an Aggressive Phenotype in Hepatocellular Carcinoma. Dis Markers. 2019; 2019:9267046. PMC: 6387700. DOI: 10.1155/2019/9267046. View